This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys
One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally. New York City-based Findell Capital Management disclosed a new $9.5 million position in Mineralys Therapeutics (MLYS +2.75%) as of its November …